QIAGEN acquired UK companion-diagnostics firm DxS Ltd. for up to approximately $130 million ($95 million upfront plus up to $35 million in milestones), gaining the CE-marked TheraScreen KRAS and EGFR companion-diagnostic menu and associated pharma partnerships.